TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04776967

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric Compression Profile
Description: A total of 4 randomized hyperbaric treatment compression profiles (accepted standards of care) will be alternated over the patients course of treatment on a daily basis daily to the prescribed treatment depth.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric Compression Profile
Description: A total of 4 randomized hyperbaric treatment compression profiles (accepted standards of care) will be alternated over the patients course of treatment on a daily basis daily to the prescribed treatment depth.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric Compression Profile
Description: A total of 4 randomized hyperbaric treatment compression profiles (accepted standards of care) will be alternated over the patients course of treatment on a daily basis daily to the prescribed treatment depth.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric Compression Profile
Description: A total of 4 randomized hyperbaric treatment compression profiles (accepted standards of care) will be alternated over the patients course of treatment on a daily basis daily to the prescribed treatment depth.
Study: NCT02857010

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogenic mesenchymal stem cells
Description: Cell therapy

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Serum without stem cells
Study: NCT02041845

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 60 Gy in 40 fractions
Description: 3D conformal thoracic radiotherapy at a total dose of 60 Gy in 40 fractions, 2 fractions per day, 5 days a week. If doses to organs at risk exceed normal tissue tolerance, the dose may be lowered to a minimum of 54 Gy.
Study: NCT03441373

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once daily during 5 days.
Study: NCT03143712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG1690
Description: Oral administration of GLPG1690 in three different treatment conditions (treatment A through C)
Study: NCT03656718

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: (Subcutaneous) Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: (Subcutaneous) Specified dose on specified days
Study: NCT00280735

Intervention type: DRUG
Group type: OTHER
Intervention: carboplatin
Description: Carboplatin will be given intravenously,once,every 3 weeks. The carboplatin area under curve (AUC) dose will be calculated using the Calvert Equation 19 as follows: Carboplatin dose (mg) = 6x (GFR + 25)

Intervention type: DRUG
Group type: OTHER
Intervention: docetaxel
Description: 75 mg/m² intravenously, once, every 3 weeks
Study: NCT01452243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D and calcium suplementation
Description: The pharmacological intervention will be the daily administration of chewable tablets containing 800 IU of vitamin D and 1200 mg of calcium. They will be administered over 2 years during the months of November to April in order to avoid the influence of sunlight.
Study: NCT03143712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG1690
Description: Oral administration of GLPG1690 in three different treatment conditions (treatment A through C)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG1690
Description: Oral administration of GLPG1690 in three different treatment conditions (treatment A through C)
Study: NCT02201004

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TOFOGLIFLOZIN CSG452
Description: Pharmaceutical form:tablet Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TOFOGLIFLOZIN CSG452
Description: Pharmaceutical form:tablet Route of administration: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: insulin
Description: Pharmaceutical form:solution Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin
Description: Pharmaceutical form:solution Route of administration: subcutaneous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Pharmaceutical form:tablet Route of administration: oral
Study: NCT04385017

Intervention type: OTHER
Group type: OTHER
Intervention: COVID-19 patients
Description: It will consist in the collection of 2 additional tubes at their blood draw. For DNA analysis, informed consent will be collected in writing
Study: NCT00218933

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate intensity exercise training
Description: 12-weeks, 2-3 times per week moderate exercise-intensity (70% of peak heart rate)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High intensity exercise training
Description: 12-weeks, 2-3 times per week high-intensity interval-training (95% of peak heart rate)
Study: NCT00578591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m\^2 is given weekly X 4. For patients with a partial response, an additional 4 doses will be permitted as needed (after 4 weeks from the last dose).~Diagnosis of grade II to IV aGVHD will be confirmed, whenever possible, by a biopsy taken from at least one of the following three sites: skin, gut, or liver.
Study: NCT01609790

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV
Study: NCT00131937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given orally
Study: NCT04381793

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Recovery Factors
Description: Porcine serum amino acid/peptide
Study: NCT04194138

Intervention type: PROCEDURE
Intervention: Index or spine revision surgery for complex adult spinal deformity
Description: Surgical interventions will be patient specified by treating surgeon.
Study: NCT01685320

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Forces applied by laryngoscope
Description: Force and pressure distribution applied by direct or indirect laryngoscope during glottis visualization and intubation were measured using film pressure transducers.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Forces applied by laryngoscope
Description: Force and pressure distribution applied by direct or indirect laryngoscope during glottis visualization and intubation were measured using film pressure transducers.
Study: NCT02320734

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium
Description: Rocuronium given continuously to reach deep neuromuscular block
Study: NCT03679234

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine infant formula
Description: Routine infant formula with probiotic
Study: NCT03885349

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SBIP+ ADAPs-IMP
Description: Standard batterer intervention program plus Individualized Motivational Plans adapted to alcohol and/or drug abuse problems. The SBIP consist of 70 hr of a cognitive-behavioral intervention including discussion topics such as sexism, sex roles, and gender equality. The intervention phase consisted of six modules in which different intervention techniques were applied (i.e., group dynamics, roleplaying, videos, training in cognitive restructuring, emotion management skills). The IMP included a set of motivational strategies to increase treatment compliance and motivation for change and had four main strategies: (a) five individual motivational interviews, to identify IPV related personal goals and follow up their achievement (in this case, one of the goals has to be related to ADAPs); (b) three group sessions where participants share their goals; (c) therapists follow-up and reinforcement of participants' goals; and (d) use of retention techniques.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SBIP+IMP
Description: Standard batterer intervention program plus Individualized Motivational Plans. The SBIP consist of 70 hr of a cognitive-behavioral intervention including discussion topics such as sexism, sex roles, and gender equality. The intervention phase consist of six modules in which different intervention techniques are applied (i.e., group dynamics, roleplaying, videos, training in cognitive restructuring, emotion management skills). The IMP include a set of motivational strategies to increase treatment compliance and motivation for change and has four main strategies: (a) five individual motivational interviews, to identify IPV related personal goals and follow up their achievement; (b) three group sessions where participants share their goals, explain their progress to the group, and receive feedback, support and advice from the group; (c) therapists follow-up and reinforcement of participants' goals; and (d) use of retention techniques.
Study: NCT04107532

Intervention type: OTHER
Group type: OTHER
Intervention: Virtual Reality Therapy and Imagination Exposure Therapy
Description: Virtual Reality Therapy and Imagination Exposure Therapy

Intervention type: OTHER
Group type: OTHER
Intervention: Virtual Reality Therapy and Imagination Exposure Therapy
Description: Virtual Reality Therapy and Imagination Exposure Therapy
Study: NCT02553291

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SystemCHANGE

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Study: NCT01071421

Intervention type: DEVICE
Intervention: abbreviated polysomnography
Description: Both groups will be studied with in-hospital respiratory polygraphy during the sleep. The group A will be studied with another respiratory polygraphy in the home one month after the resolution of CAP. Some questionnaires to measure the sleepiness (Epworth test), FOSQ test, in-home sleepiness questionnaire and symptoms questionary will be obtained in Group A and B

Intervention type: DEVICE
Intervention: abbreviated polysomnography
Description: Both groups will be studied with in-hospital respiratory polygraphy during the sleep. The group A will be studied with another respiratory polygraphy in the home one month after the resolution of CAP. Some questionnaires to measure the sleepiness (Epworth test), FOSQ test, in-home sleepiness questionnaire and symptoms questionary will be obtained in Group A and B
Study: NCT01171794

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: 3 x 200mg (600mg total) x tid and one dosing on the subsequent day ( 4 doses total)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: identical number of visually identical tasteless pills as ibuprofen arm
Study: NCT03005717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIPO-202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIPO-202

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for LIPO-202
Description: Lyophile manufactured to mimic LIPO-202 lyophile.
Study: NCT03441620

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: strawberries
Description: Freeze-dried strawberry powder

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: strawberries
Description: Freeze-dried strawberry powder

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control powder
Description: Control powder matched for fiber and strawberries
Study: NCT04409327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTB101
Description: Oral RTB101 10 mg hard gelatin capsule once daily for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral matching placebo once daily for 4 weeks
Study: NCT02366026

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: IR103
Description: REMUNE HIV/AIDS Vaccine with two adjuvants IFA + Amplivax

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IR103
Description: REMUNE HIV/AIDS Vaccine with two adjuvants IFA + Amplivax
Study: NCT04568161

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physical Characteristics
Description: Body weight, height and waist circumference

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Muscular Sympathetic Nervous Activity
Description: Microneurography technique.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cardiac Function
Description: Echocardiography.
Study: NCT04568161

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Heart rate
Description: Electrocardiography

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood pressure
Description: Non-invasive photoplethysmography.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood Assessments
Description: Serum and Plasma will be extracted by centrifugation. Endothelial microparticles by flow cytometry Interleukin-6 and tumor necrosis factor α by ELISA, High-sensitive reactive serum C-reactive protein by immunoturbidimetric assay, NT- ProBNP According to Central Laboratory, Hospital das Clinicas, HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo. Endothelin-1 by immunoenzymatic method Nitric oxide by gas chemiluminescence Lipoperoxidation by fluorimetry Carbonyl by spectrophotometer, and Superoxide Dismutase (SOD) by colorimetry.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Muscle blood flow
Description: Venous occlusion plethysmography

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Endothelium-dependent vascular function
Description: Brachial ultrasound
Study: NCT04339621

Intervention type: DEVICE
Intervention: LiverMultiscan
Description: The LiverMultiscan is a quick 15 minute, contrast free MRI scan that provides three metrics on liver health namely fat, iron and fibro-inflammatory scores

Intervention type: DEVICE
Intervention: LiverMultiscan
Description: The LiverMultiscan is a quick 15 minute, contrast free MRI scan that provides three metrics on liver health namely fat, iron and fibro-inflammatory scores
Study: NCT04568161

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Vascular intima-media thickness
Description: Carotid ultrasound

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Physical Capacity
Description: Cardiopulmonary exercise test

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anthracycline & Cyclophosphamide treatment scheme
Description: Four session of intravenous (in bolus) infusion of doxorubicin 60mg/m2 and cyclophosphamide 600mg/m2 with an interval of 21 days between sessions.
Study: NCT04798430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lerodalcibep
Description: PCSK9 inhibitor
Study: NCT01240109

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: * propofol group : propofol effect site-TCI 2-4mcg/ml + remifentanil effect site-TCI 2-4ng/ml~* sevoflurane group: sevoflurane end-tidal concentration 0.5-1.0 MAC + remifentanil effect site-TCI 2-4ng/ml
Study: NCT01675518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP7991
Description: oral
Study: NCT00710840

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally Invasive Total Knee Arthroplasty [TKA Min]
Description: TKA Min is a procedure in which diseased and painful joint surfaces of the knee are replaced by metal and plastic components shaped to allow continued motion of the knee. TKA Min, as opposed to TKA Traditional, employs smaller skin incisions and smaller instrumentation and avoids turning the knee cap out and dislocating the knee. This procedure also avoids disrupting the knee extensor mechanism and the suprapatellar pouch and minimizes extreme knee flexion during surgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Knee Arthroplasty (TKA) Traditional
Description: TKA is a procedure in which diseased and painful joint surfaces of the knee are replaced by metal and plastic components shaped to allow continued motion of the knee.
Study: NCT01785199

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Head elevation by an automatic adjustable bed
Description: The automatic device is initiated when the patient suffers from apnea ≥ 10 seconds, which is detected by an ultra-wideband (UWB) sensor placed under the bed. The head will be slightly elevated at an angle of 10 degrees lasting 10 seconds and then be put down softly.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Head elevation by an automatic adjustable bed
Description: The automatic device is initiated when the patient suffers from apnea ≥ 10 seconds, which is detected by an ultra-wideband (UWB) sensor placed under the bed. The head will be slightly elevated at an angle of 10 degrees lasting 10 seconds and then be put down softly.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Head elevation by an automatic adjustable bed
Description: The automatic device is initiated when the patient suffers from apnea ≥ 10 seconds, which is detected by an ultra-wideband (UWB) sensor placed under the bed. The head will be slightly elevated at an angle of 10 degrees lasting 10 seconds and then be put down softly.
Study: NCT03656718

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: (Subcutaneous) Specified dose on specified days
Study: NCT01785199

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Head elevation by an automatic adjustable bed
Description: The automatic device is initiated when the patient suffers from apnea ≥ 10 seconds, which is detected by an ultra-wideband (UWB) sensor placed under the bed. The head will be slightly elevated at an angle of 10 degrees lasting 10 seconds and then be put down softly.
Study: NCT03784755

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Ablative Radiation Therapy
Description: Undergo stereotactic radiotherapy and/or surgery to all sites of disease (oligometastases and primary prostate if previously untreated).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Patients continue to receive their current planned systemic therapy at the discretion of the treating physician

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Patients continue to receive their current planned systemic therapy at the discretion of the treating physician
Study: NCT03707938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brigatinib
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local Consolidation Therapy
Description: Undergo local consolidative therapy
Study: NCT02027246

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow mononuclear cell transplantation
Description: Bone marrow is aspirated by a standard procedure. Mononuclear cells are separated by density gradient method and then injected intrathecally by a standard lumbar puncture procedure
Study: NCT02524262

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Slow-release L-cysteine
Description: Bind and inactivate acetaldehyde formed from ethanol by covalent binding to L-cysteine

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Slow-release L-cysteine
Description: Bind and inactivate acetaldehyde formed from ethanol by covalent binding to L-cysteine
Study: NCT02009111

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Couple CARE for Parents
Description: Couple CARE for Parents is a skill-based relationship enhancement program based on a self-regulatory model. It consists of seven sessions and two follow-up booster sessions that occur over the baby's first eight months of life. The first home visit is scheduled 7 - 14 days following recruitment. The next two sessions are scheduled in two week intervals. Sessions 4 through 7 are scheduled in three week intervals. Home visits are expected to last 1.5 to 2 hrs. Out-of-session viewing of the video and completing the exercises typically requires 45 min to 1 hr. The typical phone consultation lasts 15- to 30- min per person. Thus, the program lasts a minimum of 8 to 12 hours. The program will also include two booster sessions (beyond the 8 - 12 hrs).

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Couple CARE for Parents
Description: Couple CARE for Parents is a skill-based relationship enhancement program based on a self-regulatory model. It consists of seven sessions and two follow-up booster sessions that occur over the baby's first eight months of life. The first home visit is scheduled 7 - 14 days following recruitment. The next two sessions are scheduled in two week intervals. Sessions 4 through 7 are scheduled in three week intervals. Home visits are expected to last 1.5 to 2 hrs. Out-of-session viewing of the video and completing the exercises typically requires 45 min to 1 hr. The typical phone consultation lasts 15- to 30- min per person. Thus, the program lasts a minimum of 8 to 12 hours. The program will also include two booster sessions (beyond the 8 - 12 hrs).
Study: NCT00478504

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Starting daily dose 2.5 mg on menstrual cycles days 2 to 6, to be increased to 5 mg daily if there is no response to 2.5 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomifene citrate
Description: Starting daily dose 50 mg on menstrual cycles days 2 to 6, to be increased to 100 mg daily if there is no response to 50 mg
Study: NCT00605969

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Motion analysis
Description: Participants will undergo a motion analysis procedure: a dynamic assessment of the movement in their hip.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Motion analysis
Description: Participants will undergo a motion analysis procedure: a dynamic assessment of the movement in their hip.

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Computed Tomography
Description: Participants will undergo computed tomography (CT) scan of their hip.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Participants will undergo computed tomography (CT) scan of their hip.
Study: NCT03226366

Intervention type: OTHER
Intervention: Immediate evaluation by multidisciplinary team
Description: Simultaneous initial evaluation by the ED physician, nurse, and patient care associate
Study: NCT02402556

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MOCEP
Description: Through parent support and an evidence-based curriculum, MOCEP uses education to reduce risk factors that hinder children's health and wellbeing.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MOCEP
Description: Through parent support and an evidence-based curriculum, MOCEP uses education to reduce risk factors that hinder children's health and wellbeing.